Results for Cellular Immunotherapies

Dr. Myers aims to improve outcomes for children and young adults receiving cellular immunotherapies for high-risk hematologic toxicities. Her current research is focused on studying toxicities of CAR T-cell therapies through a combination of clinical epidemiologic and translational research methods.

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

Dr. Kadauke is the associate director of the Cell and Gene Therapy Laboratory at CHOP and the medical director of the Cell and Gene Therapy Informatics team. His research focuses on developing novel ways to manufacture cell therapies with the goal of accelerating and broadening patient access to these life-saving therapies.

Dr. Laetsch is a pediatric oncologist who provides clinical care and conducts research with the overarching goal of improving treatment options for children with difficult to treat cancers.